Long considered undruggable, transcription factors have finally become fair game for a clutch of innovative biotechs who are combining biological insights with innovative chemistry to bring into play a vast number of new drug targets.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Big pharma seduced by transcription factors again. What has changed?. Nat Biotechnol 43, 1587–1590 (2025). https://doi.org/10.1038/s41587-025-02862-y
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02862-y
